Hexavac
diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted
Table of contents
Overview
The marketing authorisation for Hexavac has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
Product details | |
---|---|
Name |
Hexavac
|
Agency product number |
EMEA/H/C/000298
|
Active substance |
|
International non-proprietary name (INN) or common name |
diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
J07CA
|
Publication details | |
---|---|
Marketing-authorisation holder |
Sanofi Pasteur MSD, SNC
|
Revision |
0
|
Date of issue of marketing authorisation valid throughout the European Union |
23/10/2000
|
Contact address |
Sanofi Pasteur MSD SNC
8 rue Jonas Salk F-69007 Lyon FRANCE |
Product information
28/06/2012 Hexavac - EMEA/H/C/000298 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
This combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis B caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.